Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccine Responses in Older Cancer Patients
NCT00741039Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2008
- Primary completion
- Aug 2012
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of Fluzone Trivalent and 23-valent pneumococcal polysaccharide vaccine in influenza and pneumococcal infection, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Vaccine Response Rate. Started Aug 2008; status: completed.
02
Drugs
Fluzone Trivalent23-valent pneumococcal polysaccharide vaccine
03
Conditions
influenzapneumococcal infection
Beyond the preview
Go deeper on NCT00741039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00741039.